Follow The Filings

CMPX Compass Therapeutics Inc.

Health Care, filed as COMPASS THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.8%
  • $13M
  • 1 add

In 2026 Q2 Palo Alto Investors added to Compass Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 1.8% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Add 1.8%

Who owns CMPX

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 1.8%, was 1.2% Add +285.1% 5,831,813 $13M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CMPX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CMPX insider trades
  • $97K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Neil Lerner Chief Accounting Officer
    Buy
    $18K 20,000 shares at $0.9200 +5% to stake
    Traded Oct 1 Filed Oct 2
    ↗
  2. Neil Lerner Chief Accounting Officer
    Buy
    $2,850 2,500 shares at $1.14 +0.6% to stake
    Traded Sep 24 Filed Sep 25
    ↗
  3. Neil Lerner Chief Accounting Officer
    Buy
    $28K 15,000 shares at $1.89 +3.9% to stake
    Traded Apr 29 Filed Apr 30
    ↗
  4. Jonathan Anderman General Counsel
    Buy
    $47K 25,000 shares at $1.89 +15% to stake
    Traded Apr 29 Filed Apr 30
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 stock grants and 3 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.03,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K FORM 10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $850,000 $0.00
Net income -$42.49M -$49.38M -$66.49M
Net margin * — -5808.8% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $153.88M $132.75M $209.82M
Total non-current assets * $2.99M $7.65M $9.77M
Total assets $156.88M $140.4M $219.59M
Total current liabilities $7.8M $8.87M $13.97M
Total non-current liabilities * $0.536M $6.3M $8.83M
Total equity $148.54M $125.23M $196.79M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$40.62M -$44.86M -$49.14M
Cash from investing $26.96M $46.77M -$93.31M
Cash from financing $2.94M $17.34M $129.61M
Net change in cash -$10.72M $19.26M -$12.84M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.